|
[1]
|
S. A. Kliewer, B. M. Forman, B. Blumberg, E. S. Ong, U. Borg- meyer, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proceedings of the National Academy of Sciences of the United States of America,1994, 91(15): 7355-7359.
|
|
[2]
|
E. E. Girroir, H. E. Hollingshead, P. He, B. Zhu, G. H. Perdew, et al. Quantitative expression patterns of peroxisome proliferator- activated receptor-b/d (PPARb/d) protein in mice. Biochemical and Biophysical Research Communications, 2008, 371(3): 456- 461.
|
|
[3]
|
M. Uhlén, E. Björling, C. Agaton, C. A. Szigyarto, B. Amini, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Molecular & Cellular Proteomics, 2005, 4(12): 1920- 1932.
|
|
[4]
|
L. Berglund, E. Björling, P. Oksvold, L. Fagerberg, A. Asplund, et al. A genecentric human protein Atlas for expression profiles based on antibodies. Molecular & Cellular Proteomics, 2008, 7(10): 2019-2027.
|
|
[5]
|
C. H. Lee, P. Olson, A. Hevener, I. Mehl, L. W. Chong, et al. PPARdelta regulates glucose metabolism and insulin sensitivity. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103(9): 3444-3449.
|
|
[6]
|
P. A. Grimaldi. Metabolic and nonmetabolic regulatory functions of peroxisome proliferator-activated receptor b. Current Opinion in Lipidology, 2010, 21(3): 186-191.
|
|
[7]
|
J. M. Peters, F. J. Gonzalez. Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPAR- beta/delta) in cell proliferation and cancer. Biochimica et Bio- physica Acta, 2009, 1796(2): 230-241.
|
|
[8]
|
B. P. Kota, T. H. Huang and B. D. Roufogalis. An overview on biological mechanisms of PPARs. Pharmacological Research, 2005, 51: 85-94.
|
|
[9]
|
T.-C. He, T. A. Chan, B. Vogelstein and K. W. Kinzler. PPARd is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell, 1999, 99(3): 335-345.
|
|
[10]
|
L. Yang, H. Zhang, Z. G. Zhou, H. Yan, G. Adell, et al. Biologi- cal function and prognostic significance of peroxisome prolif- erator-activated receptor {delta} in rectal cancer. Clinical Cancer Research, 2011, 17(11): 3760-3770.
|
|
[11]
|
L. Yang, B. Olsson, D. Pfeifer, J. I. Jönsson, Z. G. Zhou, et al. Knockdown of peroxisome proliferator-activated receptor-beta induces less differentiation and enhances cell-fibronectin adhe- sion of colon cancer cells. Oncogene, 2010, 29(4): 516-526.
|
|
[12]
|
L. Yang, Z. G. Zhou, H. Z. Luo, B. Zhou, Q. J. Xia, et al. Quan- titative analysis of PPARdelta mRNA by real-time RT-PCR in 86 rectal cancer tissues. European Journal of Surgical Oncology, 2006, 32(2): 181-185.
|
|
[13]
|
M. Schmuth, C. M. Haqq, W. J. Cairns, J. C. Holder, S. Dorsam, S. Chang, et al. Peroxisome proliferator-activated receptor (PPAR)- beta/delta stimulates differentiation and lipid accumulation in keratinocytes. Journal of Investigative Derma-tology, 2004, 122 (4): 971-983.
|
|
[14]
|
A. D. Burdick, D. J. Kim, M. A. Peraza, F. J. Gonzalez, J. M. Pe- ters. The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation. Cell Signal, 2006, 18(1): 9-20.
|
|
[15]
|
D. J. Kim, M. T. Bility, A. N. Billin, T. M. Willson, F. J. Gon- zalez, et al. PPAR-β/δ selectively induces differentiation and in- hibits cell proliferation. Cell Death & Differentiation, 2006, 13: 53-60.
|
|
[16]
|
F. Varnat, B. B. Heggeler, P. Grisel, N. Boucard, I. Corthésy -Theulaz, et al. PPAR-β/δ regulates paneth cell differentiation via controlling the hedgehog signaling pathway. Gastroenterol- ogy, 2006, 131(2): 538-553.
|
|
[17]
|
B. H. Park, B. Vogelstein and K. W. Kinzler. Genetic disruption of PPARd decreases the tumorigenicity of human colon cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98(5): 2598-2603.
|
|
[18]
|
F. S. Harman, C. J. Nicol, H. E. Marin, J. M. Ward, F. J. Gon- zalez, et al. Peroxisome proliferator-activated receptor-δ attenu- ates colon carcinogenesis. Nature Medicine, 2004, 10(5): 481- 483.
|
|
[19]
|
E. H. Holly, M. G. Borland, A. N. Billin, T. M. Willson, F. J. Gonzalez, et al. Ligand activation of peroxisome proliferator- activated receptor-b/d (PPARb/d) and inhibition of cyclooxy- genase 2 (COX2) attenuate colon carcinogenesis through inde- pendent signaling mechanisms. Carcinogenesis, 2008, 29(1): 169-176.
|
|
[20]
|
R. A. Gupta, R. N. Dubois. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Reviews Cancer, 2001, 1(1): 11-21.
|
|
[21]
|
D. Hanahan, J. Folkman. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86(3): 353-364.
|
|
[22]
|
E. K. Bergsland. Vascular endothelial growth factor as a thera- peutic target in cancer. American Journal of Health-System Pharmacy, 2004, 61(21): S4-S11.
|
|
[23]
|
D. Wang, H. Wang, Y. Guo, W. Ning, S. Katkuri, et al. Crosstalk between Peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proceedings of the Na- tional Academy of Sciences of the United States of America, 2006, 103(50):19069-19074.
|
|
[24]
|
H. Lin, J. L. Lee, H. H. Hou, C. P. Chung, S. P. Hsu, et al. Mo- lecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells. Journal of Cellular Physiology, 2008, 214(2): 434-441.
|
|
[25]
|
H. J. Lim, S. Lee, J. H. Park, K. S. Lee, H. E. Choi, et al. PPAR δ agonist L-165041 inhibits rat vascular smooth muscle cell pro- liferation and migration via inhibition of cell cycle. Atherosclerosis, 2009, 202(2): 446-454.
|